Mr. Shota Awata—A zero-based blockchain entrepreneur without inheriting family business

Mr. Shota Awata, a Ritsumeikan University in Japan graduate, co-founded the JCDA (Japan aging’s society of care and medical research association) with Mr. Nakamura Shuichi, who served as the Chief of Board of elderly health of Ministry of Health, Labor, and Welfare of Japan, together with Mr. Takashi Uji who served as NTT Corporation Senior. Besides, Mr. Shota is the CEO of Genkicell Chain in Japan.

Mr. Shota is the eldest son of Toridoll consortium, renowned in Japan. Subsequent to securing his Master degree of Ritsumeikan University, rather than joining his family business, he joined Synergy Marketing, a medical consulting enterprise. Mr. Shota opted for working in the healthcare sector since he had been experiencing major diseases in the period of his high school. Together with that, he had hopes of putting forward a systematic approach, which could sustain healthful conditions, away from illness.

Right from the time of working in the medical consulting sector in the year 2013, Mr. Shota has realized the fact that Japan's advanced medical standards, combined with the Internet industry, will unquestionably break through the whole industry. Currently, both the medical and health sectors are primarily based on the treatment, nevertheless, physical examination and self-diagnosis tests are incapable of forming continuous records sporadically. How to combine the Internet industry for the accomplishment of the transition from the treatment to prevention has emerged as the key emphasis of his research work. Owing to the rapid growth of China's Internet industry, Mr. Shota learned the Internet+ conception, coinciding with his philosophy. Mr. Shota made a decision to start a curve business, originating from a foreign country.

At the beginning of the year 2017, Mr. Shota aimed at valuing the health-related data, together with attaining the value loop with the help of Internet applications based on the Internet of Things terminals as well as offline agencies. Furthermore, in the meantime, the big data collection mark was classified as a starting point. Mr. Yoshinobu Shijo promoted the project growth as the CTO of Genkicell Chian.

Mr. Shijo developed a block-based technology for the collection and marking of health data from multiple sources in a bid to develop a personal health living record (PLHR), thereby realizing the marking and classification of personal health data and making sure both the consistency and standardization of data. In the mechanism of entrepreneurship, Mr. Shota invited Mr. Keichiro Yoshida, a senior analyst at Nomura Securities, for the purpose of forming an entrepreneurial iron triangle.

The Genkicell team started pouring heavy investment in the technological research and development right from the commencement of February 2017, aimed at strictly regulating itself through the supervision of the people and the government. Following a year-long accumulation, the team has bagged the preliminary results in terms of contacts, resources, data, technology, funds, etc. Besides, the project has appeared on the ground as a preparation for landing as well.

Conventional medical data, at a high-sensitivity level, deals with the writing habits of doctors, in addition to hospital cooperation attitudes, and government authorization procedures. There is quite a low probability of landing a corresponding project; in addition, the GCL vitality chain makes use of the non-high-sensitivity data as the source of data. The project has secured extensive amount of uninterrupted personal health medical data with the help of the cooperation with the Toyohashi City Government of Japan. In the meantime, it has acquired strategic benefits in terms of policy compliance and industry presence, being a member of the JCDA. Furthermore, Genkicell Chain makes a pivotal strategic partner of research institutes, for instance, Healtheone, Toyohashi University of Industrial Technology, and BIC, which are termed as renowned online health cloud platforms. They possess robust technical reserves, together with advanced technology research and development.

Mr. Shota Awata, the founder of Genkicell Chain, cast light on the fact that the Genkicell Chain is going to publicize project information between June and July 2018, followed by officially unveiling the public’s viewpoint.

The Genkicell Chain has garnered extensive attention of major cooperative enterprises in Japan, China, Southeast Asia, Europe and the United States. This time, through an entirely cautious appearance in the eyes of the public, it is worth looking forward to wait.

JMDC cooperates with Genkicell Chain!元気いっぱい!

Recently, the JMDC(Japanese Medical Data Center) officially entered into a strategic cooperation intention with the Genkicell chain, and further improved the data application of JMDC through the blockchain technology of the Genkicell chain, reducing costs and reducing hardware consumption. This collaboration will be seen as bringing the greatest innovation to the Japanese healthcare and health industry.

Left:Mr. Shota Awata (Genkicell CEO)

Middle:Mr. Matsushima Yousuke (JMDC CEO)

Right:Qi Lin (Genkicell Partner)

The Japan Medical Data Center (JMDC) was established in 2002 to expand the range and analysis of medical data and generate more and more output. This will enhance the ability of everyone in the society to access quality health care and contribute to the health of the Japanese medical community. JMDC cooperates with many well-known Japanese pharmaceutical companies, health insurance research institutes, insurance companies, etc. to conduct medical health data collection and analysis, and has a large number of actual and objective data on the visibility of personal prevention, treatment prevention and long-term care. Continuously create multiple patents, such as claims (hospital, outpatient, pharmacy) document generation system (standardization of medical data), medical information management system and medical information management method claims management and qualification information, computer programs, terminals, methods and servers (daily Healthy age).

JMDC has perfected PHR (Personal Health Record) through reliable data from major Japanese hospitals and pharmaceutical companies. In addition, JMDC has launched an electronic prescription in cooperation with Japan's major pharmacies. According to the purchaser's purchase behavior record, psychosocial information and index parameters after taking the drug, the risk of the user taking a certain drug can be revealed. This is conducive to the precise prescribing of medical staff and the later tracking of the patient's physical condition. The combination of PHR data and e-prescription combined with telemedicine technology can make a good medical solution even in remote areas, where the basic level of medical care and reading ability are low. Telemedicine technology can be said to be the embryonic form of the medical community, and it can also play a reference role in China's medical reform.

However, PHR's data collection channels are relatively limited, medical data is not spontaneously generated, the cost of collection is huge, and the uploaded data is not complete. In the implementation of telemedicine technology, the amount of data diagnosis is large, the transmission process is slow, and the hardware requirements are very high, which restricts the further development of PHR. The Genkicell chain utilizes the blockchain technology to acquire data at a lower cost. The IPFS protocol is used to store the marked health data in a distributed system. The private key in the transaction sub-directory will be given to the user to read the encrypted IPFS. The authority of the data to ensure the security of medical data. IPFS itself has high transmission speed, high reliability and no storage limit, and provides modular building customization requirements, focusing on ecological landing.

The addition of JMDC has made the Genkicell's vital health ecosystem PLHR (Personal Life Health Record) more complete, and the data information is more abundant and accurate. Through the blockchain technology, the data is classified into EMR and PHR data through daily distributed standardization judgment in the massive judgment node, and the data is filtered and optimized, so that the data structure conforms to the applicable standard of EHR, and the feature database is continuously improved. The value of these labeled and screened data will be gradually applied to improve current health services such as grading, large health management, telemedicine, cognitive diagnostic aids, and side effects studies. Future health and medical services will use PLHR to select the most effective treatment solution for the individual.

Working with JMDC will undoubtedly make the data on the chain of Genkicell chain more realistic and accurate, and the richness and data value of PLHR will gradually increase. It also makes JMDC's medical data collection and analysis more convenient and accurate, and more and more accurate and effective output to better serve the Japanese medical community and society.